Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Anboni (unecritinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sino Biopharm

Drug class:

ALK inhibitor, ROS1 inhibitor, c-MET inhibitor

Related drugs:

‹

crizotinib (312)

entrectinib (178)

alectinib (104)

lorlatinib (94)

brigatinib (50)

ensartinib (42)

repotrectinib (27)

iruplinalkib (11)

ALK inhibitor (0)

savolitinib (29)

amivantamab-vmjw (25)

capmatinib (23)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

›

ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2
ALK positive	Solid Tumor	ALK positive	Solid Tumor	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3
MET amplification	Solid Tumor	MET amplification	Solid Tumor	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3
CD74-ROS1 rearrangement	Non Small Cell Lung Cancer	CD74-ROS1 rearrangement	Non Small Cell Lung Cancer	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3	unecritinib Sensitive: C3 – Early Trials unecritinib Sensitive : C3